Stockreport

InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF JENA, Germany--(BUSINESS WIRE)-- InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, to [Read more]